PMID- 33581713
OWN - NLM
STAT- MEDLINE
DCOM- 20211006
LR  - 20211012
IS  - 1475-2840 (Electronic)
IS  - 1475-2840 (Linking)
VI  - 20
IP  - 1
DP  - 2021 Feb 13
TI  - The predictive utility of circulating PCSK9 levels on diabetes mellitus.
PG  - 45
LID - 10.1186/s12933-021-01226-5 [doi]
LID - 45
AB  - Increasing data including ours have suggested that proprotein convertase 
      subtilisin/kexin type 9 (PCSK9), a novel regulator of cholesterol metabolism, may 
      also play an important role in the development of type 2 diabetes mellitus (T2DM) 
      and is associated with clinical outcomes in diabetic patients. Previous studies 
      revealed that elevated plasma PCSK9 levels had a higher incidence of new-onset 
      T2DM. Moreover, the results of available epidemiological, preclinical, and 
      clinical studies have indicated that plasma PCSK9 concentration is correlated 
      with glycemic parameters and can predict the adverse cardiovascular events in 
      diabetic patients with coronary artery disease. However, there is currently no 
      general agreement about the association of PCSK9 with T2DM. The usefulness of the 
      circulating PCSK9 concentration as a predictor for the risk of new-onset T2DM 
      should be clinically prudential.
FAU - Peng, Jia
AU  - Peng J
AD  - State Key Laboratory of Cardiovascular Diseases, FuWai Hospital, National Center 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, No 167 BeiLiShi Road, XiCheng District, Beijing, 100037, China.
FAU - Zhu, Cheng-Gang
AU  - Zhu CG
AD  - State Key Laboratory of Cardiovascular Diseases, FuWai Hospital, National Center 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, No 167 BeiLiShi Road, XiCheng District, Beijing, 100037, China.
FAU - Li, Jian-Jun
AU  - Li JJ
AUID- ORCID: 0000-0003-2536-4364
AD  - State Key Laboratory of Cardiovascular Diseases, FuWai Hospital, National Center 
      for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, No 167 BeiLiShi Road, XiCheng District, Beijing, 100037, China. 
      lijianjun938@126.com.
LA  - eng
PT  - Comment
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210213
PL  - England
TA  - Cardiovasc Diabetol
JT  - Cardiovascular diabetology
JID - 101147637
RN  - 0 (Blood Glucose)
RN  - EC 3.4.21.- (PCSK9 protein, human)
RN  - EC 3.4.21.- (Proprotein Convertase 9)
SB  - IM
CON - Cardiovasc Diabetol. 2020 Dec 10;19(1):209. PMID: 33302966
MH  - Blood Glucose
MH  - *Coronary Artery Disease
MH  - *Diabetes Mellitus, Type 2
MH  - Humans
MH  - Proprotein Convertase 9
PMC - PMC7881449
OTO - NOTNLM
OT  - Proprotein convertase subtilisin/kexin type 9
OT  - Risks
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2021/02/15 06:00
MHDA- 2021/10/07 06:00
PMCR- 2021/02/13
CRDT- 2021/02/14 20:21
PHST- 2021/01/08 00:00 [received]
PHST- 2021/01/22 00:00 [accepted]
PHST- 2021/02/14 20:21 [entrez]
PHST- 2021/02/15 06:00 [pubmed]
PHST- 2021/10/07 06:00 [medline]
PHST- 2021/02/13 00:00 [pmc-release]
AID - 10.1186/s12933-021-01226-5 [pii]
AID - 1226 [pii]
AID - 10.1186/s12933-021-01226-5 [doi]
PST - epublish
SO  - Cardiovasc Diabetol. 2021 Feb 13;20(1):45. doi: 10.1186/s12933-021-01226-5.